Colorado-based New Iridium accelerating global production of potential COVID-19 treatment using light-driven chemistry

New Iridium photocatalysis platform can reduce manufacturing time and increase yields for many drugs and is now being tested with potential COVID-19 treatment Remdesivir

BOULDER, Colo., July 08, 2020 (GLOBE NEWSWIRE) — New Iridium, a company developing commercialized  photocatalysis technologies to accelerate drug development and manufacturing, has been awarded a National Science Foundation (NSF) Small Business Technology Transfer (STTR) grant for $256,000 to conduct research and development work on facilitating timely availability of Remdesivir, a potential life-saving drug in the global fight against COVID-19.

Learn more in the press release.

Categories: Ecosystem News